424 related articles for article (PubMed ID: 24608791)
1. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Auffinger B; Tobias AL; Han Y; Lee G; Guo D; Dey M; Lesniak MS; Ahmed AU
Cell Death Differ; 2014 Jul; 21(7):1119-31. PubMed ID: 24608791
[TBL] [Abstract][Full Text] [Related]
2. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
3. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide.
Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y
Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703
[TBL] [Abstract][Full Text] [Related]
6. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
[No Abstract] [Full Text] [Related]
8. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
9. Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Riccitelli E; Giussani P; Di Vito C; Condomitti G; Tringali C; Caroli M; Galli R; Viani P; Riboni L
PLoS One; 2013; 8(6):e68229. PubMed ID: 23826381
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Zhang S; Wan Y; Pan T; Gu X; Qian C; Sun G; Sun L; Xiang Y; Wang Z; Shi L
J Mol Neurosci; 2012 Jun; 47(2):346-56. PubMed ID: 22528454
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
12. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Zhu TZ; Li XM; Luo LH; Song ZQ; Gao X; Li ZQ; Su JY; Liang GB
Int J Oncol; 2014 Aug; 45(2):699-709. PubMed ID: 24841897
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
D'Alimonte I; Nargi E; Zuccarini M; Lanuti P; Di Iorio P; Giuliani P; Ricci-Vitiani L; Pallini R; Caciagli F; Ciccarelli R
Purinergic Signal; 2015 Sep; 11(3):331-46. PubMed ID: 25976165
[TBL] [Abstract][Full Text] [Related]
14. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH
Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
17. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM
Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
19. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
20. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]